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REVIEW CURRENTOPINION Genital inflammation, immune activation and risk
of sexual HIV acquisitionpyright © 2016 Wolters K
www.co-hivandaids.coma,b,d a,c a,bJo-Ann S. Passmore , Heather B. Jaspan , and Lindi MassonPurpose of review
Women who have genital inflammation are at increased risk of sexual HIV infection. The purpose of this
review is to evaluate the mechanisms for this relationship, causes of genital inflammation, and strategies to
manage this condition.
Recent findings
We have recently shown in a cohort of South African women that HIV seroconversion was associated with
persistently raised genital inflammatory cytokines (including MIP-1a, MIP-1b, and IP-10). Elevated
inflammatory cytokine concentrations may facilitate HIV infection by recruiting and activating HIV target
cells and disrupting the mucosal epithelial barrier. Bacterial vaginosis and sexually transmitted infections
(STIs), which are predominantly asymptomatic in women, cause lower genital tract inflammation and
increased HIV acquisition risk. In Africa, where syndromic management of STIs and bacterial vaginosis is
standard-of-care, the substantial burden of asymptomatic infections has likely contributed to high-HIV
incidence rates.
Summary
A genital inflammatory profile contributes to the high risk of HIV acquisition in African women. STIs and
bacterial vaginosis are poorly managed in Africa and other developing nations and as such remain major
drivers of persistent genital inflammation and HIV acquisition among these women.
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Young women in sub-Saharan Africa are dispropor-
tionately affected by HIV, with infection risk of up to
eight-fold higher than in men of the same age [1].
Despite new HIV infections dropping from 3.4
million in 2001 to 2.0 million globally in 2014 [2],
continued transmission in young women is one of
the greatest challenges preventing an AIDS-free
generation [3]. Susceptibility to HIV infection varies
considerably from person-to-person, with some
women remaining uninfected despite repeated
exposure [4]. Bacterial vaginosis and sexually trans-
mitted infections (STIs) [5–8], as well as other bio-
logical factors, have been shown to impact the risk of
young women acquiring HIV. Genital inflammation
underlies many of these risk factors, providing a




].Prevention at CAPRISA, University of Cape Town, Anzio Road, Observ-
atory, 7925 Cape Town, South Africa. Tel: +27 21 6507963; fax: +27 21
4066681; e-mail: Jo-ann.Passmore@uct.ac.za
Curr Opin HIV AIDS 2016, 11:156–162
DOI:10.1097/COH.0000000000000232HIV RISK AND GENITAL INFLAMMATION
Inflammation in the female genital tract, regardless
of the cause, creates an environment that favors HIVluwer Health, Inc. Unautreplication and establishment of a productive infec-
tion. Women with elevated concentrations of proin-
flammatory cytokines, including macrophage
inflammatory protein (MIP)-1a, MIP-1b and IP-10,
in their genital tracts were found to be at increased
risk of HIV acquisition [9
&&
]. Interferon gamma-
induced protein 10 (IP-10) MIP-1a, and MIP-1b
are chemotactic for HIV target cells, including T
cells, macrophages, and dendritic cells [11–14].horized reproduction of this article is prohibited.
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KEY POINTS
 Genital inflammation places women at increased risk of
HIV acquisition.
 Higher levels of cytokines in the lower genital tract
result in chemotaxis of highly activated HIV target cells
to the mucosa.
 STIs and bacterial vaginosis are major drivers of
genital inflammation.
Genital inflammation and HIV risk Passmore et al.MIP-1a and MIP-1b are also ligands for the HIV
coreceptor C–C chemokine receptor 5 (CCR5) and
specifically recruit CCR5þ target cells into tissues
[15]. Proinflammatory cytokine signatures in the
lower reproductive tract have been associated with
increased frequencies of neutrophils, T and B cells,
as well as higher levels of cellular activation
[16,17
&&
]. Proinflammatory cytokines and chemo-
kines that are involved in activation, differentiation,
and recruitment of immune cells to the genital tract
may increase HIV transmission as HIV replication
depends on the presence of immune cell targets, the
level of immune cell activation and monocyte
differentiation to macrophages or dendritic cells
[13,16]. In rhesus macaques, proinflammatory
cytokine production following vaginal simian
immunodeficiency virus (SIV) exposure resulted in
recruitment of CD4þ T cells needed for establish-
ment of SIV infection [11,18]. The essential role of
inflammation in SIV infection was clearly demon-
strated when topical application of an anti-inflam-
matory, glycerol-monolaurate, down-regulated
chemokine concentrations, inhibited inflammatory
cell influx to the genital tract, and prevented SIV
infection in macaques [11].
Studies in exposed seronegative (ESN) women,
who remained HIV-uninfected despite high-risk
sexual activity, have improved our understanding
of risk factors for HIV acquisition. In ESN women,
concentrations of the CCR5-binding chemokine
regulated on activation, normal T cell expressed
and secreted were found to be elevated compared
with low-risk controls, whereas MIP-1a and MIP-1b
have been shown to competitively inhibit HIV bind-
ing to CCR5 in vitro, suggesting that these chemo-
kines may protect against HIV infection [19,20].
However, ESN women may have higher genital che-
mokine concentrations compared with low-risk
controls because they are more likely to have STIs
[4], and in vitro models do not account for up-regu-
lation of other inflammatory factors or recruitment
of HIV target cells by these chemokines that may
facilitate HIV replication in vivo. More recent ESNopyright © 2016 Wolters Kluwer Health, Inc. Una
1746-630X Copyright  2016 Wolters Kluwer Health, Inc. All rights resestudies have shown that an immune quiescent phe-
notype in the female genital tract may account for
reduced susceptibility to HIV infection in these
women [21,22]. Although ESN women were found
to have higher CD4þ T cell numbers at the cervix,
fewer of these cells expressed CCR5 compared with
low-risk women [22].
In addition to recruiting more target cells for
HIV replication, proinflammatory cytokines induce
expression of the transcription factor, nuclear factor
(NF)-kB, which binds to HIV-long terminal repeat
and directly upregulates HIV replication [23]. Proin-
flammatory cytokines may also facilitate HIV infec-
tion by disrupting tight junctions between
epithelial cells, reducing the integrity of this barrier
[24]. In support of this, proteomic studies have
shown that women with elevated genital proinflam-
matory cytokine concentrations have unique
protein signatures of reduced epithelial barrier func-
tion [17
&&
]. Several proteins that regulate actin cytos-
keleton organization and extracellular matrix
components were found to be associated with gen-
ital inflammation, suggesting that tissue remodel-
ing occurs in women with inflammation at the
expense of effective barrier function [17
&&
].SYSTEMIC MARKERS OF INFLAMMATION,
CHEMOKINE GRADIENTS AND HIV RISK
Blood biomarkers have also been associated with
increased risk of HIV infection [25,26]. Others from
our group reported that women who later became
HIV-infected had higher plasma concentrations of
TNF-a, IL-2, IL-7, and IL-12p70 than women who
remained uninfected [25]. We found that these and
other cytokines do not correlate between blood and
the genital tract, suggesting that cytokine risk fac-
tors identified in blood do not predict those in the
genital tract and vice versa [9
&&
,27]. Kahle et al. [26]
found that elevated plasma IP-10 and IL-10 concen-
trations predicted HIV seroconversion in individ-
uals in HIV discordant relationships.
ESN women had lower concentrations of HIV-
target cell recruiting chemokines, including IP-10,
MIP-1a, and MIP-1b, in the genital tract than blood,
which may result in reduced target cell influx in the
absence of a chemokine gradient to the genital tract,
and thereby confer a certain degree of protection
against HIV infection [21,22]. This suggests that a
chemokine gradient from blood to the genital
mucosa may contribute to risk for HIV infection.
The level of T-cell activation in blood appears to
be important in HIV risk. CD4þ T-cell immune
quiescence has shown to be protective against
HIV infection in vivo [28]. Studies in European
adult ESNs showed relatively lower CD38 anduthorized reproduction of this article is prohibited.
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Immune activationHLA-DR-expressing CD4þ T cells in blood than per-
sons who go on to become HIV-infected [28]. SIV-
exposed sooty mangabey infants, with few periph-
eral and mucosal CD4þCCR5þ cells, are less likely to
acquire SIV via low-dose oral challenge than their
rhesus macaque counterparts [29]. We found a
strong correlation between peripheral and cervical
T-cell activation in HIV-uninfected women [30].
Global T-cell activation may be an important con-
tributing factor determining HIV risk.SEXUALLY TRANSMITTED INFECTIONS
CAUSE GENITAL INFLAMMATION
STIs are major causes of inflammatory cytokine
upregulation and immune cell recruitment to the
genital mucosa [27,31–34]. Although inflammation
can be important in STI clearance, it may also cause
destruction of infected epithelial layers, allowing
STI-associated microbes to access deeper tissues
[35,36]. Relatively few women are able to clear an
infection in the absence of treatment, with STIs
often being recurrent or persistent [37,38]. In
addition to reproductive complications, nonulcer-
ative STIs have been found to influence suscepti-
bility to HIV infection [5,8]. We have shown that
Chlamydia trachomatis, Neisseria gonorrhoeae, and
Mycoplasma genitalium infections were associated
with increased risk of HIV acquisition [8]. Highly
prevalent STIs, such as human papillomavirus (HPV)
infections, have also been shown to increase risk of
HIV infection [39]. Of the common STIs, we found
that Chlamydia was associated with the highest gen-
ital cytokine levels, followed by gonorrhoea, herpes
simplex virus-2 (HSV-2), trichomoniasis, and bac-
terial vaginosis [27].
In a cohort of African women, Masese et al. [40
&&
]
reported that the overall population risk for HIV
infection was largely attributable to HSV-2, even in
the absence of ulcers, with prevalent HSV-2 account-
ing for 48.3% and incident HSV-2 infections account-
ing for 4.5% of risk. Although HSV-2 ulcerative
lesions disrupt the mucosal barrier, higher numbers
of DC-SIGNþ DCs and CCR5þ CD4þ T cells are
observed in the genital tracts of women who have
HSV-2, even in the absence of HSV-2 shedding or
genital ulceration, and subclinical inflammatory
responses in the mucosa are evident for months
after a reactivation event [34,41]. Other infections,
including yeast (6.4%), Trichomonas vaginalis (1.1%),
N. gonorrhoeae (0.9%), and nonspecific cervicitis
(0.7%), accounted collectively for 9% of the popu-
lation attributable risk for HIV in an African cohort
[40
&&
]. Masese et al. [40
&&
] showed that prevalent HSV-
2 infections continued to be the most dominant
population attributable risk (40.4–61.8% betweenyright © 2016 Wolters Kluwer Health, Inc. Unaut
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mated thatover50% ofnew HIV infections inwomen
could be attributed to STIs, bacterial vaginosis and
candidiasis in 2010, with HSV-2 being the most influ-
ential infection [42].BACTERIAL VAGINOSIS AND THE
VAGINAL MICROBIOME INFLUENCE
GENITAL INFLAMMATION
Bacterial vaginosis is a syndrome characterized by a
displacement of healthy vaginal commensal micro-
biota by other Gram-positive and Gram-negative
bacteria [43,44]. A recent meta-analysis found that
bacterial vaginosis was associated with 1.7-fold
increased risk of HIV acquisition [7]. Masese et al.
[40
&&
] reported that bacterial vaginosis contributed
substantially to HIV acquisition risk, with 15.1% of
the overall population risk attributable to this con-
dition and 7.5% attributable to intermediate micro-
biota [40
&&
]. Given the high infection risk and
recurrence of bacterial vaginosis, this strong associ-
ation with HIV risk has important public health
implications.
Several studies from North America have defined
a healthy female genital tract as one harboring pre-
dominantly Lactobacillus species (particularly L. crisp-
atus and L. jensenii), having a pH between 3.5–4.5,
having no bacterial vaginosis, candida, or other STIs
[45–47], although this may not be perfectly
applicable to women in Africa [47]. Recent studies
from South Africa found that less than 40% of women
had a vaginal microbiota dominated by Lactobacillus
spp., withmore thanhalfof thewomen not having an
easily definable predominant bacterial taxon [10
&&
].
Commensal microorganisms are recognized as
an important component of vaginal mucosal
defense against STIs [48], including HIV [49–52],
but the mechanisms of this protection are not well
elucidated and are likely multifactorial. There are
several ways by which commensal bacteria could
potentially affect vaginal inflammation and HIV
susceptibility. These include: lowering vaginal pH
as a result of their lactic acid and H2O2 metabolites;
competitive antagonism of pathogens; antimicro-
bial factor production [53], modulation of epithelial





]; generation of tolerizing cells such as
Tregs [55,56]. No single bacterial strain drives all
of these effects, and it is likely that more than one of
these mechanisms may be at play, and may not be
mutually exclusive.
In vitro experiments have demonstrated that
Lactobacillus species generally induce low or no
proinflammatory cytokine production by vaginal
epithelial cell lines, compared with commonhorized reproduction of this article is prohibited.
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Genital inflammation and HIV risk Passmore et al.bacterial vaginosis-associated organisms, such as
Atopobium vaginae or Gardnerella vaginalis [57,58].
Anahtar et al. [10
&&
] found that the presence-specific
combinations of noncommensal organisms (cervi-
cotype IV defined by a high diversity of organisms,
dominated by Gardnerella and Prevotella species, but
also featuring Shuttleworthia, Sneathia, Megasphaera,
Mobiluncus, and Atopobium) was associated with
higher levels of inflammation (measured by IL-1a,
IL-1b, and TNF-a concentrations) in the genital
tracts of young African women. Only half of the
young women in this category had Nugent scores
less than 7. Some of these noncommensal bacteria
individually (Sneathia amnii, Streptococcus sanguine-
gens and Mobiluncus mulieris) induced inflammatory
responses by vaginal epithelial cell lines [10
&&
].
These women were followed longitudinally, and
changes in prevalent cervicotypes were associated
with significant increases in IL-1a, IL-1b, and TNF-a,
implying a causal relationship [10
&&
]. Other studies
have found that bacterial vaginosis is associated
with genital proinflammatory cytokine upregula-
tion, but also downregulation of some cytokines
[27,59,60]. This is likely because of the fact that
bacterial vaginosis is complex, and is not the same
syndrome in every case.
Proteomic analysis of women with increasing
levels of vaginal dysbiosis was able to identify sev-
eral cytokines and cytokine receptors that increased
with bacterial vaginosis, but also found alterations
in proteins associated with mucosal barrier break-
down, including mucus and cytoskeletal alterations
(decreased keratins and cornified envelope proteins)
[54
&&
]. Interestingly, Arnold et al. [17
&&
] reported
similar changes in women with increased genital
inflammation, implying that bacterial vaginosis
may act through these same pathways to increase
susceptibility to HIV.HORMONAL CONTRACEPTIVES AND
GENITAL INFLAMMATION
Over 50 studies have examined the association
between hormonal contraceptive use and HIV.
Some studies have found no association [61],
whereas others have found up to two-fold higher
risk of HIV acquisition in seronegative women using
any hormonal contraceptive [62]. In macaques, pro-
gesterone implants increase susceptibility to vaginal
inoculation with SIV [63]. This is thought to be
because of epithelial thinning, which can be
reversed by pretreatment with estrogen [64,65].
Studies of the effect of hormonal contraceptive
among humans on genital epithelium did not
observe the thinning seen in nonhuman primate
studies [66]. Cervical ectopy, or extension of theopyright © 2016 Wolters Kluwer Health, Inc. Una
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cervix, has been associated with hormonal contra-
ceptive use [67,68]. depot medroxyprogesterone
acetate (DMPA) may decrease vaginal colonization
by H2O2-producing Lactobacillus species [66]. Con-
versely, DMPA has been shown in cohort studies to
decrease the risk of bacterial vaginosis, but to
increase the risk of other STIs, including C. tracho-
matis and HSV-2 [69,70]. On a cellular level, hormo-
nal contraceptives have been associated with
cervical and vaginal inflammation [71–73],
increased genital tract cellular CCR5 expression
[74–76], and T-cell and macrophage mucosal traf-
ficking [77]. Conversely, DMPA may also have anti-
inflammatory effects [74,78].
Other possible causes of genital inflammation
that may influence HIV risk include vaginal hygiene
practices [79], exposure to seminal proteins [80],
lubricants [81], hormone cycling [59], and genital
schistosomiasis [82], as well as host genetics [83].MANAGEMENT OF SEXUALLY
TRANSMITTED INFECTIONS AND
BACTERIAL VAGINOSIS TO REDUCE
HIV INCIDENCE
In resource-limited settings, STIs and bacterial vag-
inosis are managed syndromically, according to the
presence of clinical signs and symptoms [84]. How-
ever, large proportions of women who have STIs or
bacterial vaginosis are asymptomatic and are thus
left untreated [8,85]. In South Africa, the imple-
mentation of syndromic management in the mid-
1990s, as well as increased condom use, resulted in a
decline in gonorrhoea, chancroid, and syphilis,
although there has been little or no evidence of
declining infection risk of other STIs and bacterial
vaginosis [42]. After the introduction in South
Africa, the proportion of new HIV infections attribu-
table to curable STIs decreased from 39 to 14%
between 1990 and 2010, however, the proportion
of HIV infections attributable to HSV-2 increased
and the contribution of bacterial vaginosis
remained unchanged [42].
The results of population-wide STI treatment
interventions for HIV prevention have been largely
disappointing [86–90]. Two of three STI syndromic
management interventions in Africa resulted in no
change in HIV acquisition [91–94], suggesting that
asymptomatic infections may play a significant role.
We have demonstrated in South African women
that asymptomatic STIs were just as inflammatory
as symptomatic infections, but only 12% of women
with laboratory confirmed STIs had clinical signs [8].
This suggests that women with asymptomatic infec-
tions are also at high risk of acquiring HIV.uthorized reproduction of this article is prohibited.
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Immune activationTreatment of HSV-2 has also been found to be
ineffective at reducing HIV infection rates [87,95].
Although HSV-2 suppressive therapy may reduce
genital ulceration, HSV-2 may induce a persistent
state of susceptibility to HIV infection because of the
ongoing inflammation it causes [34]. Bacterial vag-
inosis may also have been a significant factor con-
tributing to the failure of these interventions, as
bacterial vaginosis has proven difficult to treat, with
a recurrence rate of 50% within 6 months of anti-
biotic treatment [96].CONCLUSION
Although we do not fully understand the causes of
genital inflammation that is associated with high-
HIV acquisition risk in women, prevalent STIs and
bacterial vaginosis clearly play a major role. Syn-
dromic diagnoses of these conditions are
inadequate, with the vast majority of women
asymptomatic. Current treatment strategies for
HSV-2 and bacterial vaginosis are ineffective, with
HSV-2 suppressive therapy associated with ongoing
genital inflammation and antibiotic treatment of
bacterial vaginosis having high recurrence rates.
There is thus an urgent need for better strategies
to manage STIs and bacterial vaginosis to reduce
genital inflammation in women at high risk for
HIV infection.
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